


# PHENOSENSE HIV ENTRY ASSAY

ENVELOPE EXPRESSION VECTOR: pHIVenv



HIV-1 EXPRESSION VECTOR: pHIVlucΔU3




FIG.1A

# PHENOSENSE™ HIV: CELL ASSAY




FIG.1B

# HIV ENVELOPE EXPRESSION STRATEGIES




FIG.2

# CO-RECEPTOR TROPISM SCREEN

## CCR5-EXpressing CELLS






FIG.3A



# CO-RECEPTOR TROPISM ASSAY INTERPRETATION

3			21		
R5 CELLS	X4 CELLS	R5:X4	R5	X4	R5:X4
NO DRUG	34	26,471	67,389	72	936
R5 INHIBITOR		19,258	99		
X4 INHIBITOR		32	42,295		
% INHIB BY R5 INHIBITOR		27	100		
% INHIB BY X4 INHIBITOR		100	37		



CXCR4  
CCR5  
DUAL OR MIXED  
NON-VIABLE  
ACTIVE RLU LIMIT: 100  
TROPISM RATIO LIMIT: 5

76			95		
R5	X4	R5:X4	R5	X4	R5:X4
NO DRUG	14,982	12,020	43	72	
R5 INHIBITOR	111	10,839			
X4 INHIBITOR	8,580	3,384			
% INHIB BY R5 INHIBITOR	99	10			
% INHIB BY X4 INHIBITOR	43	72			

FIG.3B

# ENTRY INHIBITOR SUSCEPTIBILITY: FUSION INHIBITOR





FIG.4A



# REDUCED SUSCEPTIBILITY: FUSION INHIBITOR





FIG.4B



# ENTRY INHIBITOR SUSCEPTIBILITY: CCR5 INHIBITOR



DRUG: R5 INHIBITOR


CELL: CD4/CCR5

FIG.5A





# ENTRY INHIBITOR SUSCEPTIBILITY: CXCR4 INHIBITOR



DRUG: X4 INHIBITOR

CELL: CD4/CXCR4

FIG.5B



# ENVELOPE SEQUENCE AMPLIFICATION





FIG. 6





# TARGET CELL RECEPTOR AND CO-RECEPTOR EXPRESSION









FIG.7 CXCR4+CCR5 CELLS

CD4<sup>+</sup> CCR5<sup>+</sup> CELLS

CD4<sup>+</sup> CXCR4<sup>+</sup> CELLS

# INHIBITION BY CO-RECEPTOR ANTAGONISTS









FIG.8



# FUSION INHIBITOR PEPTIDES




FIG.9

